Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Cell Therapeutics Inc       US1509348835

SummaryChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

Cell Therapeutics Inc : Five Star Equities Issues New Research Reports on CTIC, PACB, SEED and STML

01/21/2014 | 08:50am US/Eastern
Recommend:
0

Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.

Cell Therapeutics Inc. (NASDAQ: CTIC) shares jumped 13.75 percent to close at $3.64 a share Friday. The stock traded between $3.40 and $3.79 on volume 13.56 million shares traded. Earlier this month, the company received notification from the FDA that the partial clinical hold on Tosedostat has been removed and all studies underway may continue. Shares of Cell Therapeutics have gained approximately 140.0 percent in the past year.

Get more information on Cell Therapeutics free access to the in-depth equity report at:
www.FiveStarEquities.com/CTIC

Pacific Biosciences of California (NASDAQ: PACB) shares spiked 14.44 percent to close at $6.50 a share Friday. The stock traded between $5.65 and $6.97 on volume 2.70 million shares traded. The company is scheduled to release Fourth Quarter and Year End 2013 results on Tuesday, February 4th. Shares of Pacific Biosciences of California have gained approximately 160.0 percent in the past year.

Get more information on Pacific Biosciences and free access to the in-depth equity report at:
www.FiveStarEquities.com/PACB

Origin Agritech Ltd. (NASDAQ: SEED) shares surged 18.81 percent to close at $2.40 a share Friday. The stock traded between $2.03 and $2.55 on volume of 2.70 million shares traded. The company recently reported an operating income of RMB18.16 million for the fiscal year 2013, compared to an operating loss of RMB (3.47) million a year ago. Shares of Origin Agritech have gained approximately 56.0 percent in the past year.

Get more information on Origin Agritech and free access to the in-depth equity report at:
www.FiveStarEquities.com/SEED

Stemline Therapeutics Inc. (NASDAQ: STML) shares soared 39.50 percent to close at $30.44 a share Friday. The stock traded between $22.00 and $30.45 on volume 1.40 million shares traded. Ivan Bergstein, M.D., Stemline's CEO, presented at the 32nd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2014. Shares of Stemline Therapeutics have gained approximately 150.0 percent in the past year.

Get more information on Stemline Therapeutics and free access to the in-depth equity report at:
www.FiveStarEquities.com/STML

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Five Star Equities
info@fivestarequities.com


© Accesswire 2014
Recommend :
0
React to this article
Latest news on CELL THERAPEUTICS INC
30m ago CTI BIOPHARMA : Expands Access To PIXUVRI® With Approval In Israel And Add-on Re..
2d ago BRAINSTORM CELL THERAPEUTICS : Receives Notice of Allowance on US Patent
07/23 CTI BIOPHARMA : BrainStorm Publishes Preclinical Multidose Study in Clinical and..
07/16 CTI BIOPHARMA : BrainStorm Publishes Preclinical Multidose Study in Clinical and..
07/11 CTI BIOPHARMA : BrainStorm Announces Publication of Preclinical Multidose Study ..
07/10 CTI BIOPHARMA : BrainStorm and Octane Biotech Report Milestone
07/09 CTI BIOPHARMA : Completes Recruitment in PERSIST-1 Pivotal Phase 3 Trial of Pacr..
07/02 CTI BIOPHARMA : BrainStorm and Octane Biotech Report Milestone
06/27 CTI BIOPHARMA : BrainStorm and Octane Successfully Construct a Bioreactor Protot..
06/21 CTI BIOPHARMA : BrainStorm Cell Therapeutics Enters Into Agreements for Private ..
Advertisement
Chart
Duration : Period :
Cell Therapeutics Inc Technical Analysis Chart | US1509348835 | 4-Traders
Income Statement Evolution
Cell Therapeutics Inc : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF